Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study

J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting

P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roché, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret

Vous souhaitez échanger
avec nos équipes

D’autres articles qui pourraient
vous intéresser

Risk Factors TFR CP-CML

Success stories - Oncologie - Facultatif

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients

Long-Term TKI Treatment Patterns

Success stories - Oncologie - Facultatif

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life”

Use of Digital Health Technology to Enable Drug Development

Oncologie

Use of Digital Health Technology to Enable Drug Development